|«« back to press releases|
TITAN PHARMACEUTICALS TO PRESENT AT CANACCORD ADAMS 28TH ANNUAL GLOBAL GROWTH CONFERENCE
SOUTH SAN FRANCISCO, CA August 7, 2008 – Titan Pharmaceuticals, Inc. (AMEX:TTP) today announced that it will be presenting at the Canaccord Adams 28th Annual Global Growth Conference on Thursday, August 14, 2008. Marc Rubin, M.D., President and CEO of Titan, will discuss the Company’s business strategy and corporate overview at 9:00 am EDT at the Intercontinental Hotel in Boston.
The presentation will be webcast live and can be accessed by visiting the investor relations section of the Company’s website at www.titanpharm.com. A replay will be available on the Titan website approximately 24 hours after the presentation and will be archived for two weeks.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc. (AMEX: TTP) is focused on the late-stage development and commercialization of innovative treatments for central nervous system disorders. In addition to Probuphine, which is Titan’s first product in clinical testing to utilize its proprietary ProNeura long term drug delivery technology, the Company is planning to develop its ProNeura sustained drug delivery technology for other potential treatment applications in which conventional treatment is limited by variability in blood drug levels and poor patient compliance. ProNeura technology was developed to address the need for a simple, practical method to achieve continuous long-term drug delivery, and potentially can provide controlled drug release on an outpatient basis over extended periods of up to 6—12 months. For more information, please visit the Company’s website at www.titanpharm.com
The press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to the Company's development program and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in development, testing, regulatory approval, production and marketing of the Company's drug candidates, adverse side effects or inadequate therapeutic efficacy of the Company's drug candidates that could slow or prevent product development or commercialization, the uncertainty of patent protection for the Company's intellectual property or trade secrets, and the Company's ability to obtain additional financing. Such statements are based on management's current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned or referred to in this press release.